1
|
Lee HC, Ou CH, Huang YC, Hou PC, Creighton CJ, Lin YS, Hu CY, Lin SC. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene 2021; 40:2407-2421. [PMID: 33664454 PMCID: PMC8016667 DOI: 10.1038/s41388-021-01718-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 02/03/2021] [Accepted: 02/15/2021] [Indexed: 02/07/2023]
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) is a malignant and lethal disease caused by relapse after androgen-deprivation (ADT) therapy. Since enzalutamide is innovated and approved by US FDA as a new treatment option for mCRPC patients, drug resistance for enzalutamide is a critical issue during clinical usage. Although several underlying mechanisms causing enzalutamide resistance were previously identified, most of them revealed that drug resistant cells are still highly addicted to androgen and AR functions. Due to the numerous physical functions of AR in men, innovated AR-independent therapy might alleviate enzalutamide resistance and prevent production of adverse side effects. Here, we have identified that yes-associated protein 1 (YAP1) is overexpressed in enzalutamide-resistant (EnzaR) cells. Furthermore, enzalutamide-induced YAP1 expression is mediated through the function of chicken ovalbumin upstream promoter transcription factor 2 (COUP-TFII) at the transcriptional and the post-transcriptional levels. Functional analyses reveal that YAP1 positively regulates numerous genes related to cancer stemness and lipid metabolism and interacts with COUP-TFII to form a transcriptional complex. More importantly, YAP1 inhibitor attenuates the growth and cancer stemness of EnzaR cells in vitro and in vivo. Finally, YAP1, COUP-TFII, and miR-21 are detected in the extracellular vesicles (EVs) isolated from EnzaR cells and sera of patients. In addition, treatment with EnzaR-EVs induces the abilities of cancer stemness, lipid metabolism and enzalutamide resistance in its parental cells. Taken together, these results suggest that YAP1 might be a crucial factor involved in the development of enzalutamide resistance and can be an alternative therapeutic target in prostate cancer.
Collapse
Affiliation(s)
- Hsiu-Chi Lee
- Department of Physiology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Chien-Hui Ou
- Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Yun-Chen Huang
- Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Pei-Chi Hou
- Department of Physiology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Chad J Creighton
- Department of Medicine, Dan L. Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX, USA
| | - Yi-Syuan Lin
- Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Che-Yuan Hu
- Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.,Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Shih-Chieh Lin
- Department of Physiology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .,Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .,Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
| |
Collapse
|
2
|
Loudas NB, Killeen AA, Palamalai V, Weight CJ, Rao A, Cho LC. Falsely Undetectable Prostate-Specific Antigen (PSA) Due to Presence of an Inhibitory Serum Factor: A Case Report and Review of Pertinent Literature. AMERICAN JOURNAL OF CASE REPORTS 2019; 20:1248-1252. [PMID: 31444319 PMCID: PMC6717398 DOI: 10.12659/ajcr.917137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Patient: Male, 63 Final Diagnosis: Recurrent prostate cancer Symptoms: Falsely undetectable PSA Medication: — Clinical Procedure: Serum dilution Specialty: Urology
Collapse
Affiliation(s)
- Nicholas B Loudas
- Department of Radiation Oncology, University of Minnesota Medical Center, Minneapolis, MN, USA
| | - Anthony A Killeen
- Department of Laboratory Medicine and Pathology, University of Minnesota Medical Center, Minneapolis, MN, USA
| | - Vikram Palamalai
- Department of Laboratory Medicine and Pathology, University of Minnesota Medical Center, Minneapolis, MN, USA
| | - Christopher J Weight
- Department of Urology, University of Minnesota Medical Center, Minneapolis, MN, USA
| | - Arpit Rao
- Deartment of Medicine, Division of Hematology, Oncology, Bone Marrow Transplantation, Masonic Cancer Center, University of Minnesota Medical Center, Minneapolis, MN, USA
| | - L Chinsoo Cho
- Department of Radiation Oncology, University of Minnesota Medical Center, Minneapolis, MN, USA
| |
Collapse
|
3
|
Lautenbach N, Müntener M, Zanoni P, Saleh L, Saba K, Umbehr M, Velagapudi S, Hof D, Sulser T, Wild PJ, von Eckardstein A, Poyet C. Prevalence and causes of abnormal PSA recovery. Clin Chem Lab Med 2018; 56:341-349. [PMID: 28763294 DOI: 10.1515/cclm-2017-0246] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 07/01/2017] [Indexed: 11/15/2022]
Abstract
BACKGROUND Prostate-specific antigen (PSA) test is of paramount importance as a diagnostic tool for the detection and monitoring of patients with prostate cancer. In the presence of interfering factors such as heterophilic antibodies or anti-PSA antibodies the PSA test can yield significantly falsified results. The prevalence of these factors is unknown. METHODS We determined the recovery of PSA concentrations diluting patient samples with a standard serum of known PSA concentration. Based on the frequency distribution of recoveries in a pre-study on 268 samples, samples with recoveries <80% or >120% were defined as suspect, re-tested and further characterized to identify the cause of interference. RESULTS A total of 1158 consecutive serum samples were analyzed. Four samples (0.3%) showed reproducibly disturbed recoveries of 10%, 68%, 166% and 4441%. In three samples heterophilic antibodies were identified as the probable cause, in the fourth anti-PSA-autoantibodies. The very low recovery caused by the latter interference was confirmed in serum, as well as heparin- and EDTA plasma of blood samples obtained 6 months later. Analysis by eight different immunoassays showed recoveries ranging between <10% and 80%. In a follow-up study of 212 random plasma samples we found seven samples with autoantibodies against PSA which however did not show any disturbed PSA recovery. CONCLUSIONS About 0.3% of PSA determinations by the electrochemiluminescence assay (ECLIA) of Roche diagnostics are disturbed by heterophilic or anti-PSA autoantibodies. Although they are rare, these interferences can cause relevant misinterpretations of a PSA test result.
Collapse
Affiliation(s)
- Noémie Lautenbach
- Department of Urology, University Hospital Zurich, Zurich, Switzerland.,Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland
| | - Michael Müntener
- Department of Urology, City Hospital Triemli Zurich, Zurich, Switzerland
| | - Paolo Zanoni
- Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland
| | - Lanja Saleh
- Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland
| | - Karim Saba
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| | - Martin Umbehr
- Department of Urology, City Hospital Triemli Zurich, Zurich, Switzerland
| | - Srividya Velagapudi
- Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland
| | - Danielle Hof
- Unilabs, Labor Dübendorf, Dübendorf, Switzerland
| | - Tullio Sulser
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| | - Peter J Wild
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | | | - Cédric Poyet
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
4
|
Navrátil V, Schimer J, Tykvart J, Knedlík T, Vik V, Majer P, Konvalinka J, Šácha P. DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening. Nucleic Acids Res 2016; 45:e10. [PMID: 27679479 PMCID: PMC5314793 DOI: 10.1093/nar/gkw853] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2016] [Revised: 09/06/2016] [Accepted: 09/15/2016] [Indexed: 12/29/2022] Open
Abstract
Human diseases are often diagnosed by determining levels of relevant enzymes and treated by enzyme inhibitors. We describe an assay suitable for both ultrasensitive enzyme quantification and quantitative inhibitor screening with unpurified enzymes. In the DNA-linked Inhibitor ANtibody Assay (DIANA), the target enzyme is captured by an immobilized antibody, probed with a small-molecule inhibitor attached to a reporter DNA and detected by quantitative PCR. We validate the approach using the putative cancer markers prostate-specific membrane antigen and carbonic anhydrase IX. We show that DIANA has a linear range of up to six logs and it selectively detects zeptomoles of targets in complex biological samples. DIANA's wide dynamic range permits determination of target enzyme inhibition constants using a single inhibitor concentration. DIANA also enables quantitative screening of small-molecule enzyme inhibitors using microliters of human blood serum containing picograms of target enzyme. DIANA's performance characteristics make it a superior tool for disease detection and drug discovery.
Collapse
Affiliation(s)
- Václav Navrátil
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic .,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Jiří Schimer
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Jan Tykvart
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Tomáš Knedlík
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Viktor Vik
- Department of Urology, Thomayer Hospital in Prague, Prague, 140 59, Czech Republic
| | - Pavel Majer
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic
| | - Jan Konvalinka
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic .,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Pavel Šácha
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic .,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| |
Collapse
|
5
|
Gauchez AS, Lamy P, Descotes J. Le PSA pris en défaut. Prog Urol 2015; 25:1121-4. [DOI: 10.1016/j.purol.2015.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 07/30/2015] [Accepted: 09/07/2015] [Indexed: 10/22/2022]
|
6
|
Domínguez A, Bayó M, Muñoz-Rodríguez J, Bellido JA, Abascal-Junquera JM, Hannaoui N, Banús JM. Repeated spurious elevation of serum prostate-specific antigen values solved by chemiluminescence analysis: A possible interference by heterophilic antibodies. Korean J Urol 2015; 56:785-7. [PMID: 26568798 PMCID: PMC4643176 DOI: 10.4111/kju.2015.56.11.785] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Accepted: 09/22/2015] [Indexed: 11/18/2022] Open
Abstract
Heterophilic antibodies are human immunoglobulins directed against various animal antigens. They can produce false-positive results in the analysis of different tumor markers, including prostate-specific antigen. This interference can lead to misdiagnosis, unnecessary tests, and overtreatment in some cases. We present herein the case of a 52-year-old man with repeated spurious elevation of prostate-specific antigen, reaching levels of 108.7 ng/mL, that were suspected to be caused by heterophilic antibodies. The interference was solved by changing the analysis technique. Real values of prostate-specific antigen were less than 1 ng/mL.
Collapse
Affiliation(s)
- Arturo Domínguez
- Urology Department, Institut Català dUrologia i Nefrologia, Barcelona, Spain
| | - Miquel Bayó
- Laboratori d'anàlisis M. Bayó, Terrassa, Spain
| | | | | | | | - Naim Hannaoui
- Urology Department, Institut Català dUrologia i Nefrologia, Barcelona, Spain
| | - Josep Maria Banús
- Urology Department, Institut Català dUrologia i Nefrologia, Barcelona, Spain
| |
Collapse
|
7
|
|
8
|
The coming of age of liquid chromatography coupled to tandem mass spectrometry in the endocrinology laboratory. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 883-884:50-8. [DOI: 10.1016/j.jchromb.2011.08.027] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2011] [Accepted: 08/19/2011] [Indexed: 02/07/2023]
|
9
|
Poyet C, Hof D, Sulser T, Müntener M. Artificial prostate-specific antigen persistence after radical prostatectomy. J Clin Oncol 2011; 30:e62-3. [PMID: 22203757 DOI: 10.1200/jco.2011.38.2788] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Cédric Poyet
- University Hospital Zürich, Zürich, Switzerland.
| | | | | | | |
Collapse
|
10
|
Bolstad N, Warren DJ, Bjerner J, Kravdal G, Schwettmann L, Olsen KH, Rustad P, Nustad K. Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera. ACTA ACUST UNITED AC 2011; 49:2001-6. [DOI: 10.1515/cclm.2011.702] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Indexed: 11/15/2022]
Abstract
AbstractHeterophilic antibodies are still an important source of interference in immunoassays. We have conducted a screening study for interference in a panel of commercially available assays using two sera known to contain high titer Fc-reactive heterophilic antibodies.The sera were distributed to laboratories participating in the Nordic External Quality Assessment cooperation (EQANord). Duplicate samples pre-blocked with aggregated murine monoclonal MAK33 were also supplied. Discrepancies (>50%) between the results for native and blocked samples were used to classify the tested assays as susceptible to interference. A total of 170 different assay kits covering 91 analytes were tested.We found that 21 assays, covering 19 different analytes, were susceptible to interference from the heterophilic antibodies in the two sera. Many of these are clinically and commercially important assays. Some of the false results were grossly elevated and could have been detrimental to patient care in a clinical setting.Heterophilic antibodies with Fc-reactivity remain a threat. A more widespread use of antibody fragments and aggregated immunoglobulin could potentially improve the heterophilic antibody resistance of assays intended for clinical use.
Collapse
|
11
|
Giovanella L, Ceriani L. Spurious increase in serum chromogranin A: the role of heterophilic antibodies. Clin Chem Lab Med 2010; 48:1497-9. [DOI: 10.1515/cclm.2010.293] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|